Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 2/20 | 0.44 |
| ▸ | RPS6KB1 | P23443 | 2/20 | 0.44 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.44 |
| ▸ | SYK | P43405 | 1/20 | 0.42 |
| ▸ | C5AR1 | P21730 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.41 |
| ▸ | PDGFRB | P09619 | 9/20 | 0.41 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.41 |
| ▸ | PDGFRA | P16234 | 3/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | KIT | P10721 | 2/20 | 0.38 |
| ▸ | FLT3 | P36888 | 2/20 | 0.38 |
| ▸ | PDE5A | O76074 | 3/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5356662 | 0.86 | KDM4E (0.48) | MAPTKDM4EMAPK1SCN9ANPSR1 | |
| SCHEMBL14407966 | 0.81 | MAPT (0.56) | MAPTKDM4EMAPK1NPSR1PDE5A | |
| SCHEMBL5368062 | 0.79 | ALDH1A1 (0.40) | MAPTKDM4EMAPK1NPSR1 | |
| SCHEMBL8012169 | 0.77 | PDE5A (0.48) | MAPTKDM4EMAPK1NPSR1PDE5A | |
| SCHEMBL5356384 | 0.76 | AURKA (0.53) | AURKARPS6KB1AURKBMAPTKDM4E | |
| SCHEMBL8374872 | 0.73 | PDE5A (0.51) | MAPTKDM4EPDE5A | |
| SCHEMBL697731 | 0.72 | SYK (0.45) | SYKC5AR1MAPK1SCN9A | |
| SCHEMBL5358500 | 0.72 | KDM4E (0.47) | AURKARPS6KB1AURKBMAPTKDM4E | |
| SCHEMBL5361326 | 0.72 | KDM4E (0.46) | AURKARPS6KB1AURKBMAPTKDM4E | |
| SCHEMBL5788524 | 0.71 | MAPT (0.35) | AURKARPS6KB1AURKBMAPTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090099175-A1 | Phosphodiesterase 10 inhibitors | MEMORY PHARMACEUTICALS CORPORATION | 2009-04-16 | — | — | US | disclosed |
| US-20090099175-A1 | Phosphodiesterase 10 inhibitors | MEMORY PHARMACEUTICALS CORPORATION | 2009-04-16 | — | — | US | disclosed |
| US-20090099175-A1 | Phosphodiesterase 10 inhibitors | MEMORY PHARMACEUTICALS CORPORATION | 2009-04-16 | — | — | US | disclosed |
| EP-1989195-A1 | PHOSPHODIESTERASE 10 INHIBITORS | Amgen Inc. (US) | 2008-11-12 | — | — | EP | disclosed |
| WO-2007103260-A1 | PHOSPHODIESTERASE 10 INHIBITORS | AMGEN INC. (US) | 2007-09-13 | — | — | WO | disclosed |
| WO-2007103260-A1 | PHOSPHODIESTERASE 10 INHIBITORS | AMGEN INC. (US) | 2007-09-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090099175-A1 | Phosphodiesterase 10 inhibitors | PDE7A, PDE7B, PDE10A | AURKA 3724/4885RPS6KB1 3955/4885AURKB 3143/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.